Teizeild
teplizumab · Sanofi Winthrop Industrie
PRIME AUTHORISED IN THE EUWhat Teizeild is used for
Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.
Approved use, as published by the European Medicines Agency.
What the labels mean
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Teizeild
- Active substance
- teplizumab
- Disease area
- Diabetes Mellitus, Type 1
- Medicine group
- Drugs used in diabetes
- ATC code
- A10XX01
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Tzield
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Teizeild used for?
Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.
What is the active substance in Teizeild?
Teizeild contains teplizumab.
Who makes Teizeild?
The EU marketing authorisation holder is Sanofi Winthrop Industrie.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU